{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:22:41Z","timestamp":1790565761170,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nordic Cancer Union"},{"DOI":"10.13039\/501100010339","name":"Ingeni\u00f8r Otto Christensens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University Hospital Rigshospitalet"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00280-020-04097-x","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T16:19:17Z","timestamp":1591719557000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"86","author":[{"given":"Rikke Hebo","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Lyngsie","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine","family":"Grell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Gerner","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Damgaard","family":"Br\u00fcnner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Als-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-4993","authenticated-orcid":false,"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-7972","authenticated-orcid":false,"given":"Jacob","family":"Nersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"3","key":"4097_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, Klausen TW, Jonsson OG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Frandsen TL, Marquart HV, Madsen HO, Noren-Nystrom U, Schmiegelow K (2018) Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia 32(3):606\u2013615. https:\/\/doi.org\/10.1038\/leu.2017.265","journal-title":"Leukemia"},{"issue":"16","key":"4097_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541\u20131552. https:\/\/doi.org\/10.1056\/NEJMra1400972","journal-title":"N Engl J Med"},{"issue":"22","key":"4097_CR3","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/jco.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J (2016) Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol 34(22):2591\u20132601. https:\/\/doi.org\/10.1200\/jco.2015.64.6364","journal-title":"J Clin Oncol"},{"issue":"1","key":"4097_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"GM Dores","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007. Blood 119(1):34\u201343. https:\/\/doi.org\/10.1182\/blood-2011-04-347872","journal-title":"Blood"},{"issue":"7","key":"4097_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/mph.0000000000000206","volume":"36","author":"K Schmiegelow","year":"2014","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine\/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36(7):503\u2013517. https:\/\/doi.org\/10.1097\/mph.0000000000000206","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"4097_CR6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1200\/jco.2000.18.7.1508","volume":"18","author":"Y Toyoda","year":"2000","unstructured":"Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, Ohara A, Ohkawa Y, Mori T, Ishimoto K, Sato T, Kaneko T, Maeda M, Koike K, Shitara T, Hoshi Y, Hosoya R, Tsunematsu Y, Bessho F, Nakazawa S, Saito T (2000) Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18(7):1508\u20131516. https:\/\/doi.org\/10.1200\/jco.2000.18.7.1508","journal-title":"J Clin Oncol"},{"key":"4097_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/978-3-642-74643-7_81","volume":"33","author":"H Riehm","year":"1990","unstructured":"Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G (1990) Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus 33:439\u2013450. https:\/\/doi.org\/10.1007\/978-3-642-74643-7_81","journal-title":"Haematol Blood Transfus"},{"issue":"4","key":"4097_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/s1470-2045(17)30154-7","volume":"18","author":"SN Nielsen","year":"2017","unstructured":"Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jonsson OG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K (2017) DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol 18(4):515\u2013524. https:\/\/doi.org\/10.1016\/s1470-2045(17)30154-7","journal-title":"Lancet Oncol"},{"issue":"17","key":"4097_CR9","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","volume":"30","author":"S Bhatia","year":"2012","unstructured":"Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, Hanby CL, Leisenring W, Yasui Y, Kornegay NM, Mascarenhas L, Ritchey AK, Casillas JN, Dickens DS, Meza J, Carroll WL, Relling MV, Wong FL (2012) Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol 30(17):2094\u20132101. https:\/\/doi.org\/10.1200\/JCO.2011.38.9924","journal-title":"J Clin Oncol"},{"issue":"3","key":"4097_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/leu.2016.274","volume":"31","author":"M Kato","year":"2017","unstructured":"Kato M, Ishimaru S, Seki M, Yoshida K, Shiraishi Y, Chiba K, Kakiuchi N, Sato Y, Ueno H, Tanaka H, Inukai T, Tomizawa D, Hasegawa D, Osumi T, Arakawa Y, Aoki T, Okuya M, Kaizu K, Kato K, Taneyama Y, Goto H, Taki T, Takagi M, Sanada M, Koh K, Takita J, Miyano S, Ogawa S, Ohara A, Tsuchida M, Manabe A (2017) Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia 31(3):580\u2013584. https:\/\/doi.org\/10.1038\/leu.2016.274","journal-title":"Leukemia"},{"issue":"17","key":"4097_CR11","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJM198304283081705","volume":"308","author":"S Zimm","year":"1983","unstructured":"Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308(17):1005\u20131009. https:\/\/doi.org\/10.1056\/NEJM198304283081705","journal-title":"N Engl J Med"},{"issue":"10","key":"4097_CR12","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V92.10.3569","volume":"92","author":"FM Balis","year":"1998","unstructured":"Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA (1998) Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 92(10):3569\u20133577","journal-title":"Blood"},{"issue":"3","key":"4097_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/clpt.1986.178","volume":"40","author":"L Lennard","year":"1986","unstructured":"Lennard L, Keen D, Lilleyman JS (1986) Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 40(3):287\u2013292. https:\/\/doi.org\/10.1038\/clpt.1986.178","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4097_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/clpt.1986.233","volume":"40","author":"H Sulh","year":"1986","unstructured":"Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M (1986) Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 40(6):604\u2013609. https:\/\/doi.org\/10.1038\/clpt.1986.233","journal-title":"Clin Pharmacol Ther"},{"key":"4097_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/146300907X167817","volume":"8","author":"J Breitkreutz","year":"2007","unstructured":"Breitkreutz J, Buckham J, Fischer R, P\u00f6stges R, Boos J (2007) Comparative in vitro studies on different 6-mercaptopurine formulations for use in children. Paediatr Perinatal Drug Ther 8:1","journal-title":"Paediatr Perinatal Drug Ther"},{"issue":"10","key":"4097_CR16","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1177\/0091270011423663","volume":"52","author":"H Mulla","year":"2012","unstructured":"Mulla H, Leary A, White P, Pandya HC (2012) A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia. J Clin Pharmacol 52(10):1610\u20131613. https:\/\/doi.org\/10.1177\/0091270011423663","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4097_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejca.2013.09.027","volume":"50","author":"TL Frandsen","year":"2014","unstructured":"Frandsen TL, Heyman M, Abrahamsson J, Vettenranta K, Asberg A, Vaitkeviciene G, Pruunsild K, Toft N, Birgens H, Hallbook H, Quist-Paulsen P, Griskevicius L, Helt L, Hansen BV, Schmiegelow K (2014) Complying with the European Clinical Trials directive while surviving the administrative pressure\u2014an alternative approach to toxicity registration in a cancer trial. Eur J Cancer 50(2):251\u2013259. https:\/\/doi.org\/10.1016\/j.ejca.2013.09.027","journal-title":"Eur J Cancer"},{"issue":"5","key":"4097_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/ejh.12097","volume":"90","author":"N Toft","year":"2013","unstructured":"Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H, Heyman M, Holm MS, Hulegardh E, Klausen TW, Marquart HV, Jonsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Asberg A, Schmiegelow K (2013) Risk group assignment differs for children and adults 1\u201345 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 90(5):404\u2013412. https:\/\/doi.org\/10.1111\/ejh.12097","journal-title":"Eur J Haematol"},{"key":"4097_CR19","unstructured":"Report WT (2016) WHO Guidance for organizations performing in vivo bioequivalence studies. Series No. 996, Annex 9"},{"issue":"7","key":"4097_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.leu.2403783","volume":"19","author":"M Arico","year":"2005","unstructured":"Arico M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T, Gadner H, Gaynon P, Horibe K, Hunger SP, Janka-Schaub G, Masera G, Nachman J, Pieters R, Schrappe M, SchmiegelowValsecchi KMG, Pui CH (2005) The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29\u201330, 2005. Leukemia 19(7):1145\u20131152. https:\/\/doi.org\/10.1038\/sj.leu.2403783","journal-title":"Leukemia"},{"issue":"12","key":"4097_CR21","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/pbc.26139","volume":"63","author":"K Schmiegelow","year":"2016","unstructured":"Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, Vettenranta K, Schroeder H, Weinshilboum R, Jensen KL, Grell K, Rosthoej S (2016) Maintenance therapy of childhood acute lymphoblastic leukemia revisited\u2014should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer 63(12):2104\u20132111. https:\/\/doi.org\/10.1002\/pbc.26139","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"4097_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM199007053230104","volume":"323","author":"G Koren","year":"1990","unstructured":"Koren G, Ferrazini G, Sulh H, Langevin AM, Kapelushnik J, Klein J, Giesbrecht E, Soldin S, Greenberg M (1990) Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323(1):17\u201321. https:\/\/doi.org\/10.1056\/NEJM199007053230104","journal-title":"N Engl J Med"},{"issue":"1","key":"4097_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc2292","volume":"8","author":"P Karran","year":"2008","unstructured":"Karran P, Attard N (2008) Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8(1):24\u201336. https:\/\/doi.org\/10.1038\/nrc2292","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4097_CR24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nm.2430","volume":"17","author":"B Diouf","year":"2011","unstructured":"Diouf B, Cheng Q, Krynetskaia NF, Yang W, Cheok M, Pei D, Fan Y, Cheng C, Krynetskiy EY, Geng H, Chen S, Thierfelder WE, Mullighan CG, Downing JR, Hsieh P, Pui CH, Relling MV, Evans WE (2011) Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 17(10):1298\u20131303. https:\/\/doi.org\/10.1038\/nm.2430","journal-title":"Nat Med"},{"issue":"9","key":"4097_CR25","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/bi9621573","volume":"36","author":"TR Waters","year":"1997","unstructured":"Waters TR, Swann PF (1997) Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 36(9):2501\u20132506. https:\/\/doi.org\/10.1021\/bi9621573","journal-title":"Biochemistry"},{"issue":"5278","key":"4097_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.273.5278.1109","volume":"273","author":"PF Swann","year":"1996","unstructured":"Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, Mace R (1996) Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273(5278):1109\u20131111. https:\/\/doi.org\/10.1126\/science.273.5278.1109","journal-title":"Science"},{"issue":"7","key":"4097_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/jco.2003.04.039","volume":"21","author":"K Schmiegelow","year":"2003","unstructured":"Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Makipernaa A, Rosthoj S, Szumlanski C, Sorensen TM, Weinshilboum R (2003) Intensification of mercaptopurine\/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 21(7):1332\u20131339. https:\/\/doi.org\/10.1200\/jco.2003.04.039","journal-title":"J Clin Oncol"},{"key":"4097_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pbc.26465","volume":"64","author":"JA Tolbert","year":"2017","unstructured":"Tolbert JA, Bai S, Abdel-Rahman SM, August KJ, Weir SJ, Kearns GL, Neville KA (2017) Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 64:8. https:\/\/doi.org\/10.1002\/pbc.26465","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04097-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T23:18:51Z","timestamp":1623194331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04097-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4097"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04097-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The 6MP pharmacokinetic study was approved by the Ethical Committee of the Capital Region of Denmark (H-3-2013-074). The study was performed in accordance with the 1964 Helsinki Declaration and its later amendments and approved by Ethical Committee of the Capital Region of Denmark (H-3-2013-074).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants or legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}